Background. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a common finding of renal involvement which is related to high incidence of mortality and morbidity. IL-6 is produced by leukocytes and intrinsic kidney cells that affects inflammation, increases mesangial cell proliferation, and also contributes to autoimmunity. Objective. To detect the serum level as well as ...

OBJECTIVE To estimate the prevalence of, and identify factors associated with, hand and wrist US alterations in a large cohort of SLE patients. METHODS One hundred and eight consecutive SLE patients were recruited and classified according to arthropathy type and the musculoskeletal item of the British Isles Lupus Assessment Group (BILAG) 2004 score. US examinations were performed on hand and ...

Accepted 23 October 2012 ABSTRACT Objectives To evaluate treatment with the peptidebased agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. Methods Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have ...

OBJECTIVES To evaluate treatment with the peptide-based agent, Lupuzor, in a double-blind, randomised, placebo-controlled study of patients with systemic lupus erythematosus. METHODS Patients who met ≥4 of the American College of Rheumatology criteria, had a score of ≥6 on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and did not have an A score on the British Isles...

OBJECTIVE To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). METHODS Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4...

Background: Patients with systemic lupus erythematosus (SLE) who received anifrolumab, a type I interferon receptor antibody, had greater BILAG–based Composite Lupus Assessment (BICLA) response rates vs placebo at Week (W)52 in the phase 2 MUSE 1 and 3 TULIP-1 TULIP-2 trials. receiving anifrolumab also fewer flares, more patients were able to taper glucocorticoids (GC) placebo. 1–3 Objectives: ...

Background: Type I interferons and other inflammatory mediators derived from plasmacytoid dendritic cells (pDCs) are implicated in systemic lupus erythematous (SLE) pathology. BIIB059 is a humanized monoclonal antibody that targets blood cell antigen 2 (BDCA2), pDC-specific receptor. The binding of to BDCA2 leads rapid internalization the surface pDCs subsequent inhibition interferon, cytokine,...

SIR, Turner-Stokes et al. [1] recently published their experience using repeat cycles of rituximab in SLE. We welcome this addition to the evidence base for rituximab. We recently published our experience using rituximab in SLE in 41 patients [2]. In general, we agree with the observations of the University College London (UCL) group in terms of response rates and time to relapse. However, ther...

To cite: Parker B, AlHusain A, Pemberton P, et al. Ann Rheum Dis 2014;73:1144–1150. ABSTRACT Background In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. Methods T...